Skip to main content

Table 1 Patient characteristics

From: Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study

  Patients (n = 107) Numbers (%)
Age (years) Mean ± SD 6.0 ± 3.1
Median (range) 5.3 (1.3–17.4)
Gender Male 62 (57.9)
Female 45 (42.1)
Region Central 45 (42.1)
Northeast 41 (38.3)
South 21 (19.6)
Health care system University-based 81 (75.7)
Community-based 26 (24.3)
Primary tumor site Adrenal 88 (82.2)
Abdominal 4 (3.7)
Thoracic 7 (6.5)
Others 8 (7.5)
Metastatic site at diagnosis Bone marrow 69 (64.5)
Bone 66 (61.7)
Lymph node 41 (38.3)
Liver 14 (13.1)
Brain 3 (2.8)
Others 7 (6.5)
Serum NSE (n = 82) Mean ± SD 455.4 ± 412.9
Median (range) 370.0 (0–2180.0)
Urine VMA (n = 86) Mean ± SD 38.2 ± 70.1
Median (range) 18.9 (0–494.0)
INRG Stage Stage M 106 (99.0)
Stage L2 (with MYCN amplification) 1 (1.0)
  1. Notes: Data are presented as mean ± SD and median (range) for continuous variables and number (%) for categorical variables
  2. Abbreviations: NSE serum neuron-specific enolase (ng/mL); VMA urine vanillylmandelic acid (mg/day); Stage M distant metastatic disease (except stage MS); Stage L2 locoregional tumor with presence of one or more image-defined risk factors
\